Your browser is no longer supported. Please, upgrade your browser.
Settings
ATNX [NASD]
Athenex, Inc.
Index- P/E- EPS (ttm)-1.73 Insider Own4.20% Shs Outstand93.43M Perf Week-4.38%
Market Cap346.89M Forward P/E- EPS next Y-0.95 Insider Trans-11.31% Shs Float65.31M Perf Month-11.46%
Income-151.80M PEG- EPS next Q-0.37 Inst Own67.40% Short Float13.80% Perf Quarter-18.46%
Sales138.50M P/S2.50 EPS this Y-2.80% Inst Trans16.76% Short Ratio1.72 Perf Half Y-73.21%
Book/sh1.69 P/B2.20 EPS next Y14.70% ROA-42.10% Target Price- Perf Year-66.99%
Cash/sh1.83 P/C2.03 EPS next 5Y- ROE-86.40% 52W Range3.52 - 15.24 Perf YTD-66.46%
Dividend- P/FCF- EPS past 5Y-13.40% ROI-42.00% 52W High-75.66% Beta0.59
Dividend %- Quick Ratio4.50 Sales past 5Y59.60% Gross Margin33.40% 52W Low5.40% ATR0.20
Employees593 Current Ratio5.10 Sales Q/Q-12.60% Oper. Margin- RSI (14)38.73 Volatility3.92% 5.19%
OptionableYes Debt/Eq0.94 EPS Q/Q-12.50% Profit Margin- Rel Volume0.18 Prev Close3.80
ShortableYes LT Debt/Eq0.93 EarningsMay 06 BMO Payout- Avg Volume5.25M Price3.71
Recom2.40 SMA20-5.37% SMA50-16.60% SMA200-54.00% Volume927,896 Change-2.37%
Mar-02-21Downgrade Truist Buy → Hold $6
Mar-02-21Downgrade SVB Leerink Outperform → Mkt Perform $22 → $5
Mar-02-21Downgrade Oppenheimer Outperform → Perform
Mar-02-21Downgrade JP Morgan Overweight → Neutral $7
Mar-01-21Downgrade Needham Buy → Hold
Feb-10-21Initiated Evercore ISI Outperform
Oct-26-20Initiated SVB Leerink Outperform $22
Jun-25-19Reiterated RBC Capital Mkts Outperform $29 → $31
May-02-19Initiated Oppenheimer Outperform $20
Mar-29-19Initiated SunTrust Buy $20
Nov-15-18Upgrade JP Morgan Neutral → Overweight
Oct-25-18Initiated Ladenburg Thalmann Buy $27
Mar-06-18Initiated Needham Buy $30
Oct-18-17Initiated JP Morgan Neutral $22.20
Sep-18-17Initiated Credit Suisse Outperform $25
Sep-15-17Initiated RBC Capital Mkts Outperform $35
Aug-04-21 02:22AM  
Jul-26-21 10:02AM  
07:00AM  
Jul-22-21 08:47AM  
Jul-20-21 10:28AM  
Jul-19-21 10:51AM  
Jul-06-21 07:00AM  
Jun-28-21 12:48PM  
Jun-07-21 02:57PM  
Jun-04-21 09:05AM  
May-21-21 09:55AM  
09:21AM  
May-17-21 07:00AM  
May-07-21 05:00PM  
May-06-21 09:35AM  
07:00AM  
06:15AM  
May-05-21 05:12PM  
08:48AM  
08:13AM  
07:00AM  
04:51AM  
May-04-21 05:04PM  
May-03-21 05:31PM  
04:00PM  
12:15PM  
12:00PM  
11:00AM  
10:39AM  
10:00AM  
10:00AM  
09:00AM  
08:39AM  
06:30AM  
12:45AM  
May-02-21 09:15PM  
02:30PM  
10:45AM  
03:37AM  
May-01-21 05:37PM  
09:30AM  
07:40AM  
Apr-30-21 09:00PM  
06:16PM  
04:30PM  
03:14PM  
01:45PM  
01:27PM  
11:50AM  
11:00AM  
09:50AM  
06:30AM  
12:40AM  
Apr-29-21 06:04PM  
04:31PM  
03:15PM  
02:49PM  
01:16PM  
11:45AM  
11:45AM  
11:00AM  
10:25AM  
10:00AM  
06:11AM  
Apr-28-21 10:09PM  
10:00PM  
09:04PM  
03:30PM  
02:30PM  
02:00PM  
01:29PM  
12:00PM  
11:25AM  
11:00AM  
10:47AM  
06:30AM  
Apr-27-21 08:45PM  
06:15PM  
05:29PM  
04:45PM  
04:05PM  
04:00PM  
11:15AM  
11:00AM  
10:41AM  
06:30AM  
Apr-26-21 11:45PM  
07:36PM  
06:00PM  
12:30PM  
11:45AM  
11:30AM  
11:15AM  
11:00AM  
11:00AM  
10:41AM  
10:38AM  
06:08AM  
Apr-25-21 02:00PM  
Apr-24-21 02:12PM  
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kwan RudolfEVP, Chief Medical OfficerMay 07Option Exercise4.5524,000109,200167,768May 07 04:58 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMay 07Option Exercise4.555,00022,7503,247,959May 07 04:46 PM
VIERLING JOHNDirectorMay 07Buy4.502501,1253,750May 10 04:19 PM
VIERLING JOHNDirectorMay 06Buy4.041,7006,8633,500May 10 04:19 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMay 06Buy3.995,00019,9503,242,959May 06 07:12 PM
CAMPBELL KIMDirectorMay 06Buy4.031,7507,05210,000May 07 04:13 PM
WU JINNDirectorMay 05Option Exercise4.5550,000227,500353,208May 05 05:33 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMay 05Option Exercise4.5525,000113,7503,237,959May 05 05:24 PM
CAMPBELL KIMDirectorApr 05Buy4.428,25036,4658,250Apr 07 04:15 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 22Option Exercise4.5510,00045,5003,212,959Mar 22 04:21 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 19Option Exercise4.5520,00091,0003,202,959Mar 19 04:12 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 17Option Exercise4.5520,00091,0003,182,959Mar 17 05:02 PM
Zuo William WeiPresident, China DivisionMar 04Sale4.52419,9311,898,088142,883Mar 08 04:39 PM
WU JINNDirectorMar 03Sale4.7598,000465,500303,208Mar 04 04:13 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardDec 09Option Exercise4.5510,00045,5003,162,959Dec 09 05:21 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardDec 01Buy13.311,00013,3103,152,959Dec 01 04:19 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardNov 10Buy11.951,00011,9503,151,959Nov 10 04:10 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardNov 06Buy11.705,00058,5003,150,959Nov 06 06:36 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 24Buy11.951,00011,9503,145,959Sep 24 04:14 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 21Buy12.421,00012,4203,144,959Sep 21 04:53 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 14Buy11.001,800,00019,800,00013,532,467Sep 14 03:47 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 14Buy11.951,00011,9503,143,959Sep 14 04:09 PM
Fok MansonDirectorSep 12Buy11.0316,491181,8961,999,609Sep 14 04:21 PM
Fok MansonDirectorSep 11Buy11.3913,509153,8681,983,118Sep 14 04:21 PM
WU JINNDirectorSep 11Buy11.0510,000110,500401,208Sep 14 04:16 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 11Buy10.911,00010,9103,142,959Sep 14 04:09 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 11Buy10.992,00021,9783,141,959Sep 11 04:10 PM
YORDON JEFFREYSee RemarksSep 10Option Exercise11.0018,180199,980237,106Sep 10 04:44 PM
Kanfer JordanDirectorSep 10Buy11.494505,1704,634Sep 11 04:20 PM
WU JINNDirectorSep 10Buy11.1520,000223,000391,208Sep 11 04:16 PM
Sze RandollChief Financial OfficerSep 10Buy11.401,00011,4006,000Sep 10 04:48 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 10Buy11.2210,000112,2003,139,959Sep 10 04:38 PM
Davis Stephanie ADirectorSep 10Buy11.3510,000113,50020,000Sep 14 04:24 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 10Buy11.24200,0002,248,00011,732,467Sep 14 03:47 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 21Option Exercise4.555,00022,7503,129,959Aug 21 04:09 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 20Option Exercise4.5510,00045,5003,124,959Aug 20 04:14 PM